1
|
AlKhelb D, Burke EL, Zvonok A, Iliopoulos-Tsoutsouvas C, Georgiadis MO, Jiang S, Ho TC, Nikas SP, Makriyannis A, Desai RI. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201. Eur J Pharmacol 2023; 960:176168. [PMID: 38059442 DOI: 10.1016/j.ejphar.2023.176168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 09/30/2023] [Accepted: 10/26/2023] [Indexed: 12/08/2023]
Abstract
The synthetic forms of delta-9-tetrahydrocannabinol (Δ9-THC), dronabinol or nabilone, have been approved to treat several indications. However, due to safety concerns their clinical utility remains limited. Consequently, there is a need for developing cannabinoid (CB) ligands that display better behavioral pharmacological profiles than Δ9-THC. Here, we utilized drug discrimination methods to compare the interoceptive effects of CB ligands that vary in potency, efficacy, and selectivity at the CB receptors, including two ligands, AM411 and AM4089, that show CB1 partial agonist-like actions in vitro. Male rats were trained to discriminate 0.1 mg/kg AM2201 from saline under a fixed-ratio (FR) 10 response schedule of food reinforcement. After establishing AM2201's discriminative-stimulus effects, pretreatment tests with the CB1 antagonist/inverse agonist rimonabant blocked AM2201's effects, whereas the peripherally-restricted antagonist AM6545 had no effect. Next, the generalization profiles of AM411 and AM4089 with CB1 full agonists (JWH-018, CP-55,940, AM8936), partial agonist (Δ9-THC), and non-cannabinoids (fentanyl, atropine) were compared. The CBs either fully (AM2201, CP-55,940, JWH-018, AM8936, Δ9-THC) or partially (AM411, AM4089) substituted for AM2201, whereas fentanyl and atropine did not produce AM2201-like effects. All CB drugs were more potent than Δ9-THC and correlation analysis confirmed that the relative behavioral potencies of CBs corresponded strongly with their relative affinities at the CB1 but not CB2 receptors. Together, our results further demonstrate that AM411 and AM4089 exhibit better pharmacological profiles compared to Δ9-THC, in that they are more potent and display in vivo partial agonist-like actions that are centrally mediated via CB1 receptors.
Collapse
Affiliation(s)
- Dalal AlKhelb
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 12371, Saudi Arabia
| | - Emily L Burke
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Alexander Zvonok
- MAK Scientific LLC, 151 South Bedford Street, Burlington, MA, 01803, USA
| | - Christos Iliopoulos-Tsoutsouvas
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Markos-Orestis Georgiadis
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Shan Jiang
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Thanh C Ho
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Spyros P Nikas
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Alexandros Makriyannis
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA; MAK Scientific LLC, 151 South Bedford Street, Burlington, MA, 01803, USA.
| | - Rajeev I Desai
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA; Department of Psychiatry, Behavioral Biology Program, Integrative Neurochemistry Laboratory, McLean Hospital - Harvard Medical School, Belmont, MA, 02478, USA.
| |
Collapse
|
2
|
Georgiadis MO, Kourbeli V, Papanastasiou IP, Tsotinis A, Taylor MC, Kelly JM. Synthesis and evaluation of novel 2,4-disubstituted arylthiazoles against T. brucei. RSC Med Chem 2019; 11:72-84. [PMID: 33479605 PMCID: PMC7522794 DOI: 10.1039/c9md00478e] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 11/22/2019] [Indexed: 01/10/2023] Open
Abstract
2-{2-[3-(1-Adamantyl)-4-fluorophenyl]thiazol-4-yl}ethan-1-amine (1a) and 2-{2-[4-(1-adamantyl)phenyl]thiazol-4-yl}ethan-1-amine (2a) exhibit activity against T. brucei in the range of IC50 = 0.42 μM and IC50 = 0.80 μM, respectively.
The design, synthesis and pharmacological evaluation of the 4-substituted-2-[3-(adamant-1-yl)-4-fluorophenyl]thiazoles 1a–j, the 4-substituted-2-[4-(adamant-1-yl)phenyl]thiazoles 2a–h, the 2-substituted-4-[4-(adamant-1-yl)phenyl]thiazoles 3a–e, the N-substituted 2-phenylthiazol-4-ethylamides 4a, b and the N-substituted 4-phenylthiazol-2-ethylamides 4c, d is described. Compounds 1a and 2a exhibit trypanocidal activity in the range of IC50 = 0.42 μM and IC50 = 0.80 μM, respectively. Both of these derivatives bear a lipophilic end, which consists of a 4-(1-adamantyl) phenyl or a 3-(1-adamantyl)phenyl moiety, a 1,3-thiazole ring and a functional end, which comprises of an alkylamine and can be considered as promising candidates for the treatment of Trypanosoma brucei infections.
Collapse
Affiliation(s)
- Markos-Orestis Georgiadis
- Division of Pharmaceutical Chemistry , Department of Pharmacy , School of Health Sciences , National and Kapodistrian University of Athens , Panepistimioupoli-Zografou , 157 84 Athens , Greece .
| | - Violeta Kourbeli
- Division of Pharmaceutical Chemistry , Department of Pharmacy , School of Health Sciences , National and Kapodistrian University of Athens , Panepistimioupoli-Zografou , 157 84 Athens , Greece .
| | - Ioannis P Papanastasiou
- Division of Pharmaceutical Chemistry , Department of Pharmacy , School of Health Sciences , National and Kapodistrian University of Athens , Panepistimioupoli-Zografou , 157 84 Athens , Greece .
| | - Andrew Tsotinis
- Division of Pharmaceutical Chemistry , Department of Pharmacy , School of Health Sciences , National and Kapodistrian University of Athens , Panepistimioupoli-Zografou , 157 84 Athens , Greece .
| | - Martin C Taylor
- Department of Pathogen Molecular Biology , London School of Hygiene and Tropical Medicine , Keppel Street , London WC1 E7HT , UK
| | - John M Kelly
- Department of Pathogen Molecular Biology , London School of Hygiene and Tropical Medicine , Keppel Street , London WC1 E7HT , UK
| |
Collapse
|
3
|
Georgiadis MO, Kourbeli V, Ioannidou V, Karakitsios E, Papanastasiou I, Tsotinis A, Komiotis D, Vocat A, Cole ST, Taylor MC, Kelly JM. Synthesis of diphenoxyadamantane alkylamines with pharmacological interest. Bioorg Med Chem Lett 2019; 29:1278-1281. [PMID: 30981579 DOI: 10.1016/j.bmcl.2019.04.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/02/2019] [Accepted: 04/05/2019] [Indexed: 01/31/2023]
Abstract
In this work, the synthesis and the pharmacological evaluation of diphenoxyadamantane alkylamines Ia-f and IIa-f is described. The new diphenoxy-substituted adamantanes share structural features present in trypanocidal and antitubercular agents. 1-Methylpiperazine derivative Ia is the most potent against T. brucei compound, whilst its hexylamine congener IIf exhibits a significant antimycobacterial activity.
Collapse
Affiliation(s)
- Markos-Orestis Georgiadis
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece
| | - Violeta Kourbeli
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece
| | - Vaya Ioannidou
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece
| | - Evangelos Karakitsios
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece
| | - Ioannis Papanastasiou
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece.
| | - Andrew Tsotinis
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 157 84 Athens, Greece
| | - Dimitri Komiotis
- Department of Biochemistry and Biotechnology, Laboratory of Bioorganic Chemistry, University of Thessaly, 41221 Larissa, Greece
| | - Anthony Vocat
- Global Health Institute, École Polytechnique Fédérale de Lausanne, Station 19, 1015 Lausanne, Switzerland
| | - Stewart T Cole
- Global Health Institute, École Polytechnique Fédérale de Lausanne, Station 19, 1015 Lausanne, Switzerland; Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, France
| | - Martin C Taylor
- Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 E7HT, UK
| | - John M Kelly
- Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 E7HT, UK
| |
Collapse
|
4
|
Georgiadis MO, Karoutzou O, Foscolos AS, Papanastasiou I. Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity. Molecules 2017; 22:E1408. [PMID: 28841173 PMCID: PMC6151391 DOI: 10.3390/molecules22091408] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 08/22/2017] [Accepted: 08/23/2017] [Indexed: 01/01/2023] Open
Abstract
Sigma receptor (σR) ligands have proven to be useful as cancer diagnostics and anticancer therapeutics and their ligands have been developed as molecular probes in oncology. Moreover, various σR ligands generate cancer cell death in vitro and in vivo. These σR ligands have exhibited promising results against numerous human and rodent cancers and are investigated under preclinical and clinical study trials, indicating a new category of drugs in cancer therapy.
Collapse
Affiliation(s)
- Markos-Orestis Georgiadis
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 15784 Athens, Greece.
| | - Olga Karoutzou
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 15784 Athens, Greece.
| | - Angeliki-Sofia Foscolos
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 15784 Athens, Greece.
| | - Ioannis Papanastasiou
- School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupoli-Zografou, 15784 Athens, Greece.
| |
Collapse
|
5
|
Vlachou M, Siamidi A, Spaneas D, Lentzos D, Ladia P, Anastasiou K, Papanastasiou I, Foscolos AS, Georgiadis MO, Karalis V, Kellici T, Mavromoustakos T. In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II). Drug Res (Stuttg) 2017; 67:653-660. [DOI: 10.1055/s-0043-114012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
AbstractThe aim of the present investigation was to develop matrix tablet formulations for the in vitro controlled release of two new tuberculocidal adamantane aminoethers (compounds III and IV), congeneric to the adamantane derivative SQ109, which is in final clinical trials, and aminoethers (I) and (II), using carefully selected excipients, such as polyvinylpyrrolidone, sodium alginate and lactose. The tablets were prepared using the direct compression method and dissolution experiments were conducted using the US Pharmacopoeia type II apparatus (paddle method) in gastric and intestinal fluids. The results suggest that both analogues, albeit more lipophilic than SQ109, and aminoethers (I) and (II), have the requisite in vitro release characteristics for oral administration. In conclusion, these formulations merit further assessment by conducting in vivo studies, at a later stage.
Collapse
Affiliation(s)
- Marilena Vlachou
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Angeliki Siamidi
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Dimitrios Spaneas
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Dimitrios Lentzos
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Polixeni Ladia
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Konstantina Anastasiou
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Ioannis Papanastasiou
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Angeliki-Sofia Foscolos
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Markos-Orestis Georgiadis
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Vangelis Karalis
- School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Tahsin Kellici
- Department of Chemistry, Laboratory of Organic Chemistry, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| | - Thomas Mavromoustakos
- Department of Chemistry, Laboratory of Organic Chemistry, National and Kapodistrian University of Athens, University Campus, Athens, Greece
| |
Collapse
|